Tempest Therapeutics, Inc.

Tempest Therapeutics, Inc.

Biotechnology • Healthcare • Brisbane, CA, United States • TPST (NCM)

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

415 798 8589 2000 Sierra Point Parkway, Brisbane, CA 94005, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Tempest turns to Factor for lifeline, trading majority stake for CAR-Ts and CEO - Fierce Biotech
Fierce Biotech • Nov 19
Why Tempest Therapeutics (TPST) Stock Is Down 45% Today - Benzinga
Benzinga • Nov 19
Tempest’s third makeover | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline
Oncology Pipeline • Nov 20
Tempest Therapeutics stock falls after $4.25 million direct offering - Investing.com
Investing.com • Nov 25
Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027 - Yahoo Finance
Yahoo Finance • Nov 19

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Tempest Therapeutics, Inc. had layoffs?
No layoff events have been recorded for Tempest Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Tempest Therapeutics, Inc. have?
Tempest Therapeutics, Inc. has approximately 24 employees.
What industry is Tempest Therapeutics, Inc. in?
Tempest Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Tempest Therapeutics, Inc. a publicly traded company?
Yes, Tempest Therapeutics, Inc. is publicly traded under the ticker symbol TPST on the NCM. The company has a market capitalization of approximately $0.01 billion.
Where is Tempest Therapeutics, Inc. headquartered?
Tempest Therapeutics, Inc. is headquartered in Brisbane, CA, United States at 2000 Sierra Point Parkway, Brisbane, CA 94005, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.